Emmaus Life Sciences, Inc.
EMMA
$0.016
$0.00053.23%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -43.73% | -28.22% | -29.64% | 15.71% | 60.94% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.73% | -28.22% | -29.64% | 15.71% | 60.94% |
| Cost of Revenue | -10.51% | -39.70% | -57.45% | -41.79% | -48.15% |
| Gross Profit | -45.31% | -27.45% | -27.40% | 21.51% | 78.81% |
| SG&A Expenses | -29.06% | -23.43% | -23.23% | -8.26% | 13.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.82% | -26.30% | -26.68% | -12.06% | 4.33% |
| Operating Income | -153.50% | -97.65% | -1,038.55% | 141.96% | 153.75% |
| Income Before Tax | -69.41% | 23.28% | -1.96% | 61.49% | 64.11% |
| Income Tax Expenses | 149.15% | -228.99% | -1,150.00% | -154.25% | -198.33% |
| Earnings from Continuing Operations | -72.86% | 26.28% | -1.08% | 63.06% | 64.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.86% | 26.28% | -1.08% | 63.06% | 64.87% |
| EBIT | -153.50% | -97.65% | -1,038.55% | 141.96% | 153.75% |
| EBITDA | -152.41% | -94.91% | -697.62% | 143.01% | 154.68% |
| EPS Basic | -39.06% | 41.23% | 19.51% | 69.60% | 65.43% |
| Normalized Basic EPS | -104.12% | 14.99% | 12.13% | 68.73% | 73.02% |
| EPS Diluted | -58.39% | 18.58% | 16.51% | 67.96% | 63.56% |
| Normalized Diluted EPS | -103.81% | 2.40% | 2.05% | 65.10% | 68.73% |
| Average Basic Shares Outstanding | 19.09% | 18.12% | 15.45% | 12.24% | 7.40% |
| Average Diluted Shares Outstanding | 18.40% | 17.70% | 57.25% | 54.79% | 50.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |